Gilead licenses Viread with eight India-based companies

By Elaine Rigoli

Tampa, Fla., Sept. 22 - Gilead Sciences, Inc. has signed eight new non-exclusive license agreements with generic companies in India.

These licensing agreements grant to Alkem Laboratories Ltd., Aurobindo Pharma Ltd., FDC Ltd., J.B. Chemicals & Pharmaceuticals Ltd., Matrix Laboratories Ltd., Medchem International, Ranbaxy Laboratories and Shasun Chemicals & Drugs Ltd. the rights to produce and distribute generic versions of tenofovir disoproxil fumarate (tenofovir DF) to 95 low-income countries around the world, including India.

Tenofovir DF is sold by Gilead under the brand name Viread.

The Foster City, Calif.-based biopharmaceutical company said the license agreements require that the generic companies meet certain national and international regulatory standards and include a technology transfer to enable expeditious production of large volumes of high-quality generic versions of tenofovir DF.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.